The estimated breast cancer HR for carriers of pathogenic CHEK2 variants was 4.9 (95% CI 2.5–9.5; p < 0.0001), meaning that carriers are estimated to have breast cancer incidences that are 4.9 times those for non-carriers. This evidence concerns the gene CHEK2 and breast cancer.